IGC · IGC Pharma, Inc.
$0.24
-0.02 (-7.34%)
At close · Jul 29
Going-concern doubt
— cleared May 15, 2026
The latest filing states the doubt was alleviated.
“raise substantial doubt about its ability to continue as a going concern. The Company is currently in the clinical trial stage and has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses, as well as negative cash flow from operations, in the near future.”View the 10-Q filed May 15, 2026
Market Cap
$25.92M
Shares
100.09M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-06-29 | 17,824 | $0.26 | $4,634 |
| 2026-06-24 | 669 | $0.27 | $181 |
| 2026-06-16 | 56,466 | $0.28 | $15,810 |
| 2026-06-12 | 67,262 | $0.28 | $18,833 |
| 2026-06-04 | 86,723 | $0.30 | $26,017 |
| 2026-05-27 | 9,215 | $0.29 | $2,672 |
| 2026-05-14 | 231 | $0.30 | $69 |
Showing 1–7 of 7 settlements